The diagnosis of systemic lupus erythematosus (SLE) is challenging, owing to its varied, often nonspecific, clinical manifestations. The European League Against Rheumatism/American College of Rheumatology classification criteria are a useful diagnostic tool. Several novel therapeutics for SLE are on the horizon.
Deconditioning is common in patients who experience frailty, prolonged immobility and bed rest, injury and social isolation. Management involves a multidisciplinary team comprised of GPs, specialists and allied health professionals.
Jean C. Lu, Elif Ekinci, David O'Neal, Richard J. MacIsaac
Diabetes is the leading cause of end-stage kidney disease in Western countries. Early identification and a multifaceted approach, including novel treatments developed over the past decade, can slow progression of kidney disease in people with type 2 diabetes.
Nicole Lim, Jenny Hepschke, Minas Coroneo, Ashish Agar
Glaucoma vision loss is silent, gradual and irreversible. Early detection is crucial and relies on awareness of patient risk factors, available screening tools and recommended surveillance.
Statins are standard therapy for lipid management in patients at high atherosclerotic cardiovascular risk. However, managing adverse events and the inability to achieve target lipid levels remain key challenges and should be addressed on an individual basis.
Finerenone was recently PBS listed as an adjunct to standard therapy for selected patients with type 2 diabetes and albuminuric chronic kidney disease.
In BriefClinical news with comment from local experts
